Marksans Pharma Limited has received final approval from the United States Food and Drug Administration (US FDA) for its abbreviated new drug application (ANDA) to market Pregabalin capsules in the American market. The clearance covers an extensive dosage range — 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg, and 300 mg — expanding the Indian pharmaceutical manufacturer’s portfolio in the high-demand central nervous system (CNS) therapeutics category.
The product is a generic version of Lyrica capsules, originally developed and marketed by Upjohn US 2 LLC, and is indicated for the management of neuropathic pain associated with diabetic peripheral neuropathy, postherpetic neuralgia, spinal cord injury, and other nerve damage-related conditions. The approval provides Marksans Pharma with an opportunity to compete in a market segment valued at approximately USD 263 million in annual sales, according to IQVIA MAT data for March 2022.
What does US FDA approval of Pregabalin capsules mean for Marksans Pharma’s US market ambitions?
The US FDA’s final approval for Pregabalin capsules strengthens Marksans Pharma’s positioning in the United States, a market that has historically been a significant contributor to the company’s revenue. The clearance enables the firm to introduce a therapeutically equivalent and bioequivalent alternative to Lyrica capsules, offering prescribers and patients a lower-cost option while maintaining the same safety, efficacy, and quality standards.
Pregabalin is classified as an anticonvulsant and neuropathic pain agent. It works by calming overactive nerves, which can contribute to the perception of chronic pain. By addressing conditions such as diabetic neuropathy and postherpetic neuralgia — both of which have high prevalence rates among US patients — the drug sits within a therapeutic area with sustained prescription volumes.
From a commercial standpoint, approval in multiple dosage strengths gives Marksans Pharma the flexibility to target a wider spectrum of prescribing needs, from initial titration doses to maintenance regimens. This breadth of offering can be particularly valuable in winning market share in a generic segment, where product availability across all reference-listed drug strengths can influence formulary inclusion and wholesale adoption.
How significant is the Pregabalin market opportunity in the United States?
According to IQVIA MAT data for March 2022, the annual sales for Pregabalin capsules in the United States are estimated at USD 263 million. While this figure represents the cumulative market for all manufacturers marketing the drug, it underscores the substantial commercial opportunity for new entrants with competitive pricing and strong supply chain execution.
The Lyrica brand, developed by Pfizer and marketed in the US through Upjohn, lost market exclusivity in 2019, triggering a wave of generic launches from multiple companies. Despite price erosion typical of post-patent markets, Pregabalin remains a high-volume molecule due to its broad range of indications and the chronic nature of the conditions it treats.
For Marksans Pharma, entry into this space aligns with its strategy of focusing on niche generics with steady demand profiles rather than pursuing high-risk, complex patent challenges. By leveraging manufacturing efficiencies and regulatory compliance, the company can position itself as a reliable supplier to US pharmacies, wholesalers, and integrated delivery networks.
Why is US FDA compliance critical for Indian pharmaceutical exports?
US FDA approval is a prerequisite for any drug manufacturer intending to market prescription products in the United States. For Indian pharmaceutical companies like Marksans Pharma, this regulatory green light not only validates product quality but also reinforces the firm’s credibility with global buyers.
The American market is known for stringent manufacturing, packaging, and labeling requirements. Compliance with Current Good Manufacturing Practices (cGMP) and successful completion of facility inspections are essential for securing approvals. Marksans Pharma’s ability to achieve final approval for multiple dosage strengths of Pregabalin capsules indicates that its manufacturing processes and documentation met the US FDA’s exacting standards.
In the competitive generic drug landscape, reliability of supply is often as important as pricing. Supply disruptions, particularly in essential drugs like Pregabalin, can prompt healthcare providers to seek alternative sources. By establishing itself as a consistent, compliant supplier, Marksans Pharma can strengthen relationships with US distributors and pharmacy benefit managers (PBMs).
How does Pregabalin fit into Marksans Pharma’s therapeutic focus areas?
Marksans Pharma operates with a focus on over-the-counter (OTC) and prescription pharmaceutical products across therapeutic segments including pain management, cardiovascular health, central nervous system disorders, and gastrointestinal care. The addition of Pregabalin capsules further builds the company’s presence in the CNS category, complementing existing products aimed at chronic neurological and pain-related conditions.
The CNS therapeutic area is considered relatively resilient to market volatility, as many of its key treatments cater to chronic conditions requiring long-term medication. By diversifying within this category, Marksans Pharma can better balance its portfolio and reduce dependency on single-product revenue streams.
What competitive dynamics could influence Marksans Pharma’s market entry?
Although the US Pregabalin market is already populated by multiple generic manufacturers, pricing competition is not the only determinant of market share. Contracting strategies with group purchasing organizations (GPOs), national pharmacy chains, and large healthcare systems can significantly affect uptake.
Some competitors have sought to differentiate themselves through ready availability of all dosage forms, proactive inventory management, and robust customer support. Marksans Pharma’s approval for eight dosage strengths positions it well in this regard, potentially allowing it to meet diverse prescription needs without stock shortages.
Moreover, the company’s operational base in India gives it a cost-advantage in manufacturing, which could be leveraged in negotiations with US buyers. However, given the degree of price compression in mature generics, sustained profitability will require careful cost management and efficiency in logistics.
Sector backdrop: How Indian pharmaceutical firms are expanding in the US generics market
India is one of the largest suppliers of generic medicines to the United States, accounting for a significant portion of the prescriptions filled each year. This position has been bolstered by the country’s strong base of US FDA-approved manufacturing facilities and its track record in producing high-quality, affordable drugs.
Over the past decade, Indian pharmaceutical companies have increased their presence in complex generics, injectables, and specialty segments, while maintaining a robust offering in oral solids such as capsules and tablets. The approval of Pregabalin capsules for Marksans Pharma reflects this ongoing trend of Indian firms broadening their product lines in high-volume therapeutic areas.
While the US generics market presents lucrative opportunities, it also poses challenges in terms of compliance, litigation risk, and competition. Continuous investment in quality systems, regulatory expertise, and supply chain resilience is essential for maintaining a competitive edge.
Marksans Pharma’s path forward with Pregabalin in the US
With final approval in hand, Marksans Pharma is positioned to initiate product launch planning for Pregabalin capsules across all approved strengths in the United States. Market penetration will depend on the company’s ability to secure contracts with key distributors, manage pricing pressures, and maintain an uninterrupted supply chain.
Given the chronic nature of the conditions treated by Pregabalin, patient adherence and repeat prescriptions can help sustain demand once initial market entry is achieved. Over time, success in this segment could encourage Marksans Pharma to pursue further US FDA approvals for additional CNS drugs or expand into related therapeutic categories.
While competition remains intense, the combination of multi-strength approval, existing manufacturing capability, and market demand offers a strong foundation for growth.
Discover more from Business-News-Today.com
Subscribe to get the latest posts sent to your email.
